Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients
Avtorji:Kopač, Maruša (Avtor)
Rijavec, Matija (Avtor)
Korošec, Peter (Avtor)
Bidovec, Urška (Avtor)
Kern, Izidor (Avtor)
Vantur, Romana (Avtor)
Škrgat, Sabina (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction.
Leto izida:2022
Založnik:MDPI
Izvor:Švica
UDK:616.2
ISSN pri članku:2075-4426
COBISS_ID:92821507 Povezava se odpre v novem oknu
DOI:10.3390/jpm12010070 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Maruša Kopač Šokić in Matija Rijavec sta enakovredna prva avtorja; Opis z dne 11. 1. 2022; Članek št. 70;
Število ogledov:37
Število prenosov:20
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (805,99 KB)
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-4426/12/1/70
 
Nadgradivo:J. pers. med.
MDPI
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2022 by the authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:07.01.2022

Arhiv

niGradiv

Nazaj